Spiro Gavaris appointed as President of Lupin's US Generics Business
Mumbai: Global pharma major Lupin Limited has announced the appointment of Spiro Gavaris as President U.S. Generics business. As part of Lupin's senior leadership team, Spiro will be responsible for the overall strategy, implementation, and growth of Lupin's U.S. Generics business.
Spiro joins Lupin with significant experience in the branded, generic, and biotech industries. He most recently served as President of Specialty Generics business at Mallinckrodt Pharmaceuticals and the President of US Injectables at Hikma.
Commenting on the appointment, Vinita Gupta, CEO, Lupin said, "Spiro brings strong pharma and biotech experience and has an established track record of success in building generics business across platforms, and in particular on the injectables front. We are delighted to welcome him to our leadership team."
Read also: Lupin arm acquires right to Limbitrol, Bacrocin and 7 other medicines from Bausch Health
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastrointestinal (GI), central nervous system (CNS), and women's health areas. The company invested 8.7% of its revenue on research and development in FY22.
Lupin has 15 manufacturing sites, 7 research centres and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.
Read also: Lupin unveils generic equivalent of Perforomist Inhalation Solution in US
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd